These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 9893961)
21. Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody. Wu D; Pardridge WM Drug Metab Dispos; 1998 Sep; 26(9):937-9. PubMed ID: 9733674 [TBL] [Abstract][Full Text] [Related]
22. Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Capala J; Barth RF; Bendayan M; Lauzon M; Adams DM; Soloway AH; Fenstermaker RA; Carlsson J Bioconjug Chem; 1996; 7(1):7-15. PubMed ID: 8741985 [TBL] [Abstract][Full Text] [Related]
23. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pardridge WM; Kang YS; Buciak JL Pharm Res; 1994 May; 11(5):738-46. PubMed ID: 8058646 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. Wu D; Song BW; Vinters HV; Pardridge WM J Drug Target; 2002 May; 10(3):239-45. PubMed ID: 12075825 [TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740 [TBL] [Abstract][Full Text] [Related]
26. Binding properties of biotinylated epidermal growth factor to its receptor on cultured cells and tissue sections. Spitzer E; de Los Angeles M; Perez R; Grosse R J Cell Biochem; 1989 Oct; 41(2):47-56. PubMed ID: 2613746 [TBL] [Abstract][Full Text] [Related]
27. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Ulbrich K; Hekmatara T; Herbert E; Kreuter J Eur J Pharm Biopharm; 2009 Feb; 71(2):251-6. PubMed ID: 18805484 [TBL] [Abstract][Full Text] [Related]
28. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. Cerletti A; Drewe J; Fricker G; Eberle AN; Huwyler J J Drug Target; 2000; 8(6):435-46. PubMed ID: 11328669 [TBL] [Abstract][Full Text] [Related]
29. Characterization of EGF coupling to aminated silicone rubber surfaces. Klenkler BJ; Sheardown H Biotechnol Bioeng; 2006 Dec; 95(6):1158-66. PubMed ID: 16817187 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and brain uptake of lactoferrin in rats. Ji B; Maeda J; Higuchi M; Inoue K; Akita H; Harashima H; Suhara T Life Sci; 2006 Jan; 78(8):851-5. PubMed ID: 16165165 [TBL] [Abstract][Full Text] [Related]
31. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. Pang Z; Lu W; Gao H; Hu K; Chen J; Zhang C; Gao X; Jiang X; Zhu C J Control Release; 2008 Jun; 128(2):120-7. PubMed ID: 18436327 [TBL] [Abstract][Full Text] [Related]
33. Targeted cellular delivery of quantum dots loaded on and in biotinylated liposomes. Sigot V; Arndt-Jovin DJ; Jovin TM Bioconjug Chem; 2010 Aug; 21(8):1465-72. PubMed ID: 20715851 [TBL] [Abstract][Full Text] [Related]
34. Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors. Yang W; Barth RF; Adams DM; Soloway AH Cancer Res; 1997 Oct; 57(19):4333-9. PubMed ID: 9331095 [TBL] [Abstract][Full Text] [Related]
35. Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin. Muzykantov VR; Murciano JC; Taylor RP; Atochina EN; Herraez A Anal Biochem; 1996 Oct; 241(1):109-19. PubMed ID: 8921172 [TBL] [Abstract][Full Text] [Related]
36. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980 [TBL] [Abstract][Full Text] [Related]
37. Brain delivery of biotinylated NGF bounded to an avidin-transferrin conjugate. Li XB; Liao GS; Shu YY; Tang SX J Nat Toxins; 2000 Feb; 9(1):73-83. PubMed ID: 10701183 [TBL] [Abstract][Full Text] [Related]
38. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Wu G; Barth RF; Yang W; Chatterjee M; Tjarks W; Ciesielski MJ; Fenstermaker RA Bioconjug Chem; 2004; 15(1):185-94. PubMed ID: 14733599 [TBL] [Abstract][Full Text] [Related]
39. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. Suzuki T; Wu D; Schlachetzki F; Li JY; Boado RJ; Pardridge WM J Nucl Med; 2004 Oct; 45(10):1766-75. PubMed ID: 15471847 [TBL] [Abstract][Full Text] [Related]
40. Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Xin H; Jiang X; Gu J; Sha X; Chen L; Law K; Chen Y; Wang X; Jiang Y; Fang X Biomaterials; 2011 Jun; 32(18):4293-305. PubMed ID: 21427009 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]